Acquisitions and License Agreements (Narrative) (Details) $ in Millions	12 Months Ended
Dec. 27, 2019 USD ($)
Business Acquisition [Line Items]
Noninterest Income, Other Operating Income	$ 39.0
Silence Therapeutics [Member]
Business Acquisition [Line Items]
R&D upfront payment	$ 20.0

Amount of revenue earned, classified as other, excluding interest income.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-03(1)(e))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(13))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(4))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Name:	us-gaap_NoninterestIncomeOtherOperatingIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration